B-type natriuretic peptides: prognostic markers in stable coronary artery disease

References

• Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimaki I. Incidence and prognostic implications of stable angina pectoris among women and men. JAMA295(12), 1404–1411 (2006).
   PubMed Web of Science ®Google Scholar
• Timmis AD, Feder G, Hemingway H. Prognosis of stable angina pectoris: why we need larger population studies with higher endpoint resolution. Heart93(7), 786–791 (2007).
   PubMedGoogle Scholar
• Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med.347(3), 161–167 (2002).
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr, Camargo CA, Anwaruddin S et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol.95(8), 948–954 (2005).
   PubMed Web of Science ®Google Scholar
• Masson S, Latini R, Anand IS et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin. Chem.52(8), 1528–1538 (2006).
   PubMed Web of Science ®Google Scholar
• Omland T, Aakvaag A, Bonarjee VV et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation93(11), 1963–1969 (1996).
   PubMed Web of Science ®Google Scholar
• Omland T, Persson A, Ng L et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation106(23), 2913–2918 (2002).
   PubMed Web of Science ®Google Scholar
• James SK, Lindahl B, Siegbahn A et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation108(3), 275–281 (2003).
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Morrow DA, Bentley JH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med.345(14), 1014–1021 (2001).
   PubMed Web of Science ®Google Scholar
• Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N. Engl. J. Med.352(7), 666–675 (2005).
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA297(2), 169–176 (2007).
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Braun S, Niemoller K et al. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation112(14), 2102–2107 (2005).
   PubMed Web of Science ®Google Scholar
• Richards M, Nicholls MG, Espiner EA et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J. Am. Coll. Cardiol.47(1), 52–60 (2006).
   PubMed Web of Science ®Google Scholar
• Omland T, Sabatine MS, Jablonski KA et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J. Am. Coll. Cardiol.50(3), 205–214 (2007).
   PubMed Web of Science ®Google Scholar
• de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet362(9380), 316–322 (2003).
   PubMed Web of Science ®Google Scholar
• Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr. Rev.24(3), 341–356 (2003).
   PubMed Web of Science ®Google Scholar
• Tamura N, Ogawa Y, Yasoda A, Itoh H, Saito Y, Nakao K. Two cardiac natriuretic peptide genes (atrial natriuretic peptide and brain natriuretic peptide) are organized in tandem in the mouse and human genomes. J. Mol. Cell Cardiol.28(8), 1811–1815 (1996).
   Google Scholar
• Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc. Natl Acad. Sci. USA97(15), 8525–8529 (2000).
   PubMed Web of Science ®Google Scholar
• Wu F, Yan W, Pan J, Morser J, Wu Q. Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J. Biol. Chem.277(19), 16900–16905 (2002).
   PubMed Web of Science ®Google Scholar
• Hama N, Itoh H, Shirakami G et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation92(6), 1558–1564 (1995).
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Morss A, Tung R et al. Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study. Crit. Care10(1), R37 (2006).
   PubMed Web of Science ®Google Scholar
• Yandle TG. Biochemistry of natriuretic peptides. J. Intern. Med.235(6), 561–576 (1994).
   Google Scholar
• Pemberton CJ, Johnson ML, Yandle TG, Espiner EA. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension36(3), 355–359 (2000).
   PubMed Web of Science ®Google Scholar
• Morita E, Yasue H, Yoshimura M et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation88(1), 82–91 (1993).
   PubMed Web of Science ®Google Scholar
• D’Souza SP, Yellon DM, Martin C et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am. J. Physiol. Heart Circ. Physiol.284(5), H1592–H1600 (2003).
   Google Scholar
• D’Souza SP, Baxter GF. B type natriuretic peptide: a good omen in myocardial ischaemia? Heart89(7), H707–709 (2003).
   PubMedGoogle Scholar
• Kikuta K, Yasue H, Yoshimura M et al. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am. Heart J.132(1 Pt 1), 101–107 (1996).
   PubMedGoogle Scholar
• Talwar S, Squire IB, Downie PF, Davies JE, Ng LL. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart84(4), 421–424 (2000).
   PubMed Web of Science ®Google Scholar
• Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation108(24), 2987–2992 (2003).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, de Lemos JA et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J. Am. Coll. Cardiol.44(10), 1988–1995 (2004).
   PubMed Web of Science ®Google Scholar
• Weber M, Dill T, Arnold R et al. N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am. Heart J.148(4), 612–620 (2004).
   PubMed Web of Science ®Google Scholar
• Feringa HH, Elhendy A, Bax JJ et al. Baseline plasma N-terminal pro-B-type natriuretic peptide is associated with the extent of stress-induced myocardial ischemia during dobutamine stress echocardiography. Coron. Artery Dis.17(3), 255–259 (2006).
   Google Scholar
• Chatha K, Alsoud M, Griffiths MJ et al. B-type natriuretic peptide in reversible myocardial ischaemia. J. Clin. Pathol.59(11), 1216–1217 (2006).
   PubMed Web of Science ®Google Scholar
• Staub D, Jonas N, Zellweger MJ et al. Use of N-terminal pro-B-type natriuretic peptide to detect myocardial ischemia. Am. J. Med.118(11), 1287 (2005).
   PubMed Web of Science ®Google Scholar
• Foote RS, Pearlman JD, Siegel AH, Yeo KT. Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. J. Am. Coll. Cardiol.44(10), 1980–1987 (2004).
   PubMed Web of Science ®Google Scholar
• Karabinos I, Karvouni E, Chiotinis N et al. Acute changes in N-terminal pro-brain natriuretic peptide induced by dobutamine stress echocardiography. Eur. J. Echocardiogr.8(4), 265–274 (2007).
   Google Scholar
• Goetze JP, Christoffersen C, Perko M et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J.17(9), 1105–1107 (2003).
   PubMed Web of Science ®Google Scholar
• Casco VH, Veinot JP, Kuroski de Bold ML, Masters RG, Stevenson MM, De Bold AJ. Natriuretic peptide system gene expression in human coronary arteries. J. Histochem. Cytochem.50(6), 799–809 (2002).
   Google Scholar
• Kragelund C, Gronning B, Omland T et al. Is N-terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease? Am. Heart J.151(3), 712 (2006).
   Google Scholar
• Arakawa N, Nakamura M, Aoki H, Hiramori K. Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J. Am. Coll. Cardiol.27(7), 1656–1661 (1996).
   PubMed Web of Science ®Google Scholar
• Richards AM, Nicholls MG, Yandle TG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation97(19), 1921–1929 (1998).
   PubMed Web of Science ®Google Scholar
• Omland T, de Lemos JA, Morrow DA et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am. J. Cardiol.89(4), 463–465 (2002).
   PubMed Web of Science ®Google Scholar
• Morrow DA, de Lemos JA, Blazing MA et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA294(22), 2866–2871 (2005).
   PubMed Web of Science ®Google Scholar
• Morrow DA, de Lemos JA, Sabatine MS et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J. Am. Coll. Cardiol.41(8), 1264–1272 (2003).
   PubMed Web of Science ®Google Scholar
• de Winter RJ, Stroobants A, Koch KT et al. Plasma N-terminal pro-B-type natriuretic peptide for prediction of death or nonfatal myocardial infarction following percutaneous coronary intervention. Am. J. Cardiol.94(12), 1481–1485 (2004).
   PubMed Web of Science ®Google Scholar
• Schnabel R, Rupprecht HJ, Lackner KJ et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur. Heart J.26(3), 241–249 (2005).
   PubMed Web of Science ®Google Scholar
• Schnabel R, Lubos E, Rupprecht HJ et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J. Am. Coll. Cardiol.47(3), 552–558 (2006).
   PubMed Web of Science ®Google Scholar
• Omland T, Richards AM, Wergeland R, Vik-Mo H. B-type naturietic peptide and long-term survival in patients with stable coronary artery disease. Am. J. Cardiol.95(1), 24–28 (2005).
   PubMedGoogle Scholar
• Tang WH, Steinhubl SR, Van LF et al. Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy. Am. Heart J.153(1), 36–41 (2007).
   Google Scholar
• Kragelund C, Gustafsson I, Omland T et al. Prognostic value of NH2-terminal pro B-type natriuretic peptide in patients with diabetes and stable coronary heart disease. Diabetes Care29(6), 1411–1413 (2006).
   Google Scholar
• Ndrepepa G, Braun S, Schomig A, Kastrati A. Accuracy of N-terminal pro-brain natriuretic peptide to predict mortality in various subsets of patients with coronary artery disease. Am. J. Cardiol.100(4), 575–578 (2007).
   Google Scholar
• Blankenberg S, McQueen MJ, Smieja M et al. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation114(3), 201–208 (2006).
   PubMed Web of Science ®Google Scholar
• Richards AM, Doughty R, Nicholls MG et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia–New Zealand Heart Failure Group. Circulation99(6), 786–792 (1999).
   PubMed Web of Science ®Google Scholar
• Richards AM, Doughty R, Nicholls MG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia–New Zealand Heart Failure Group. J. Am. Coll. Cardiol.37(7), 1781–1787 (2001).
   PubMed Web of Science ®Google Scholar
• Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet362(9386), 782–788 (2003).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342(3), 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med.351(20), 2058–2068 (2004).
   PubMed Web of Science ®Google Scholar
• Mueller C. The use of B-type natriuretic peptides in coronary artery disease: utile or futile? J. Am. Coll. Cardiol.50(3), 215–216 (2007).
   Google Scholar
• Emberson JR, Ng LL, Armitage J, Bowman L, Parish S, Collins R. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J. Am. Coll. Cardiol.49(3), 311–319 (2007).
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Braun S, Mehilli J, Schomig A, Kastrati A. Accuracy of N-terminal probrain natriuretic peptide to predict mortality or detect acute ischemia in patients with coronary artery disease. Cardiology109(4), 249–257 (2007).
   Google Scholar
• Nieminen MS, Bohm M, Cowie MR et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur. Heart J.26(4), 384–416 (2005).
   PubMed Web of Science ®Google Scholar
• Paulus WJ, Tschope C, Sanderson JE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur. Heart J.28(20), 2539–2550 (2007).
   PubMed Web of Science ®Google Scholar